Immuneering Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Revenue	0	0.32	2.08	2.31	1.92
Revenue Growth (YoY)	-	-84.76%	-10.02%	20.41%	-
Cost of Revenue	0	0.16	1.15	1.28	1.22
Gross Profit	0	0.16	0.93	1.03	0.7
Selling, General & Admin	16.76	15.61	8.27	3.11	2.71
Research & Development	41.62	36.27	26.54	15	4.28
Other Operating Expenses	0.03	0.03	0	0	0
Operating Expenses	58.41	51.9	34.81	18.11	6.99
Operating Income	-58.41	-51.74	-33.89	-17.08	-6.29
Interest Expense / Income	0	0	0	0	0.35
Other Expense / Income	-4.94	-1.23	-0.04	-0.04	1.07
Pretax Income	-53.47	-50.51	-33.84	-17.04	-7.71
Income Tax	0	0	-0.31	0	0
Net Income	-53.47	-50.51	-33.54	-17.04	-7.71
Shares Outstanding (Basic)	28	26	14	5	4
Shares Outstanding (Diluted)	28	26	14	5	4
Shares Change	7.69%	93.84%	175.00%	40.00%	-
EPS (Basic)	-1.88	-1.91	-2.46	-3.44	-2.18
EPS (Diluted)	-1.88	-1.91	-2.46	-3.44	-2.18
Free Cash Flow	-49.31	-44.84	-30.91	-14.67	-4.46
Free Cash Flow Per Share	-1.74	-1.70	-2.27	-2.96	-1.26
Gross Margin	-	50.11%	44.56%	44.61%	36.29%
Operating Margin	-	-16325.77%	-1629.17%	-739.01%	-327.71%
Profit Margin	-	-15937.29%	-1612.33%	-737.17%	-401.59%
Free Cash Flow Margin	-	-14148.44%	-1486.17%	-634.83%	-232.48%
EBITDA	-52.71	-49.72	-33.68	-16.96	-7.34
EBITDA Margin	-	-15685.90%	-1619.46%	-733.74%	-382.35%
Depreciation & Amortization	0.76	0.8	0.16	0.08	0.02
EBIT	-53.47	-50.51	-33.84	-17.04	-7.36
EBIT Margin	-	-15937.29%	-1627.11%	-737.17%	-383.29%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).